Invasive aspergillosis is uncommon in immunocompetent hosts but is the second most common opportunistic fungal infection in immunocompromised patients. There has been a dramatic increase in the incidence of life-threatening aspergillosis during the past 2 decades, and the morbidity and mortality of these infections despite antifungal therapy remain unacceptably high. We describe a patient kith amphotericin B-resistant Aspergillus flavus successfully treated with caspofungin, an agent belonging to a new class of antifungal drugs. Caspofungin shows great promise in the treatment of invasive aspergillosis.
机构:
Univ Manchester, N Manchester Gen & Hope Hosp, Dept Infect Dis & Trop Med, Manchester, Lancs, EnglandUniv Manchester, N Manchester Gen & Hope Hosp, Dept Infect Dis & Trop Med, Manchester, Lancs, England
机构:
BROOKE ARMY MED CTR, DEPT MED, DERMATOL SERV, FT SAM HOUSTON, TX 78234 USABROOKE ARMY MED CTR, DEPT MED, DERMATOL SERV, FT SAM HOUSTON, TX 78234 USA
机构:
Univ Manchester, N Manchester Gen & Hope Hosp, Dept Infect Dis & Trop Med, Manchester, Lancs, EnglandUniv Manchester, N Manchester Gen & Hope Hosp, Dept Infect Dis & Trop Med, Manchester, Lancs, England
机构:
BROOKE ARMY MED CTR, DEPT MED, DERMATOL SERV, FT SAM HOUSTON, TX 78234 USABROOKE ARMY MED CTR, DEPT MED, DERMATOL SERV, FT SAM HOUSTON, TX 78234 USA